After Piper Jaffray and Stifel Nicolaus gave Alnylam Pharma (NASDAQ: ALNY) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Alan Carr maintained a Buy rating on Alnylam Pharma today and set a price target of $135.00. The company’s shares closed last Monday at $80.42.
According to TipRanks.com, Carr is a 2-star analyst with an average return of 0.0% and a 39.2% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
Currently, the analyst consensus on Alnylam Pharma is a Strong Buy with an average price target of $131.83, a 62.6% upside from current levels. In a report issued on September 22, Cowen & Co. also maintained a Buy rating on the stock with a $120.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $96.08 and a one-year low of $60.27. Currently, Alnylam Pharma has an average volume of 698.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.
